AOC Cheers Psychedelics Reform as NDAA Amendments Advance

Photo by Mark Stebnicki via Pexels.

The House just voted to give the Pentagon's psychedelics research program six more years of runway, stretching a study authorization originally set to lapse into a nine-year effort running through September 2033. Buried inside the annual defense policy bill, the amendment doesn't grab headlines the way an executive order does, but it quietly extends one of the only federally sanctioned paths for studying psilocybin and MDMA in a country where both remain Schedule I substances.

Rep. Alexandria Ocasio-Cortez, who has spent years pushing similar measures through Congress with mixed results, told Marijuana Moment that psilocybin is showing something rare: early clinical promise for treatment-resistant PTSD, a condition that has stubbornly resisted conventional pharmaceuticals for a lot of veterans and trauma survivors. The amendments are now attached to the House-passed National Defense Authorization Act for Fiscal Year 2027, though what the Senate does with them is anyone's guess. This all comes just months after President Trump signed an executive order in April directing federal agencies to fast-track psychedelic compounds through the FDA, a move that reframed what had been a fringe research niche into something with real executive-branch backing.

What the New Amendments Actually Do

Photo by RDNE Stock project via Pexels.

The mechanics of the amendment are narrow but consequential. It takes the existing Department of Defense psychedelics research authorization law and swaps out a single number: three years becomes nine. Practically, that means DOD is now required to extend research performance funded under this section all the way to September 30, 2033, instead of letting the authorization quietly expire on its original short timeline. The underlying law had already set aside $10 million specifically to fund military-connected psychedelic studies, money that otherwise would have run its course with nothing guaranteeing a follow-up appropriation or renewed legal authority to keep the work going.

AOC's Long Fight for Psychedelic Research

Photo by Marek Piwnicki via Pexels.

Just as notable is the language tucked into the House Armed Services Committee's accompanying report, which urges Pentagon officials to pay closer attention to actual access pathways -- not just funding studies, but figuring out how servicemembers might eventually receive psychedelic-assisted therapies if the research pans out. That's a meaningfully different ask than simply keeping a research line alive; it signals lawmakers want DOD thinking ahead to implementation, not just data collection. All of this now rides inside the House-passed NDAA for Fiscal Year 2027, a massive must-pass bill that still has to clear the Senate, where the psychedelics provisions haven't been publicly addressed one way or another.

Trump's Executive Order Set the Stage

Photo by Wal Saravia via Pexels.

Ocasio-Cortez isn't new to this fight. She told Marijuana Moment she has introduced some version of a psilocybin measure practically every year she's served in Congress, cycling through research funding proposals, access provisions, and even descheduling attempts depending on what vehicle was available. Her first real swing came in 2019, an NDAA amendment aimed at psychedelics research that got crushed 91 to 331 -- a lopsided defeat that reflected just how unserious Congress treated the idea at the time.

Why the Military Angle Matters

Photo by Gökhan Tahincioğlu via Pexels.

Two years later, in 2021, a similar amendment failed again, but the margin had tightened considerably to 147 to 276. That's not a win, but it's a meaningful shift -- roughly 60 more votes in favor in two years, evidence that the political ground was moving even if the outcome hadn't changed yet. By 2022, Ocasio-Cortez led a separate NDAA amendment specifically directing DOD to study psilocybin and MDMA for servicemembers, part of a broader pattern of chipping away at the issue from multiple angles rather than betting everything on one bill.

What Happens Next

Photo by BookBabe via Pixabay.

What she keeps coming back to in interviews is the narrowness of the case she's making. She's not arguing psilocybin is a cure-all or that recreational access should follow automatically. She's pointing specifically to treatment-resistant PTSD -- veterans and others who have cycled through SSRIs, talk therapy, and every standard intervention without relief -- and noting that psilocybin is one of a very short list of substances showing early promise for that specific population. It's a deliberately clinical, harm-reduction framing, and it's likely part of why the vote margins have moved even among members who'd never support broader drug policy reform.

Go back and look at that 91-331 vote from 2019 and it's hard not to be struck by how far this has traveled in under a decade. A measure that got buried by a nearly four-to-one margin is now embedded in a House-passed defense bill, backed by a presidential executive order, and openly discussed by a sitting FDA commissioner in terms of weeks rather than years. That's not the normal pace of federal drug policy, which tends to move in decades, not news cycles.

But momentum isn't the same as durability. Whether this turns into a real, lasting research infrastructure or just another pilot program that quietly expires when political attention shifts depends entirely on what the Senate does with the NDAA in the coming months. Conference committees have killed plenty of promising House provisions before, and psychedelics advocates have been burned by near-misses in the past.

For the veterans and trauma survivors this is actually supposed to help, the political scoreboard matters less than the practical timeline. Extended research authorization and an executive order are not the same thing as an approved therapy sitting on a pharmacy shelf or a VA treatment protocol. The real question isn't whether Washington's mood has shifted -- it clearly has -- but how quickly that shift turns into something a person with treatment-resistant PTSD can actually access, legally, through a doctor, rather than reading about in a news story about congressional vote counts.